MeiraGTx

Clinical-stage gene therapy company with broad pipeline.

MeiraGTx (NASDAQ: MGTX) is a vertically integrated, clinical-stage gene therapy company, with six programmes in clinical development and a broad pipeline of earlier-stage assets.

The company combines expertise in viral vector design, optimisation and manufacturing with a proprietary gene regulation platform, enabling more precise and scalable therapeutic development. Its portfolio-led strategy brings together licensed, acquired and internally developed technologies, building depth across both modalities and indications.

MeiraGTx is initially focused on areas of high unmet need, including inherited retinal diseases, neurodegenerative conditions and severe xerostomia, with programmes targeting the eye, central nervous system and salivary gland. Over time, it aims to expand into additional indications, applying its platform to a wider range of serious diseases.

The MeiraGTx journey so far:

2015: the company was founded
2018: IPO on NASDAQ for $100 million
2022: $25 million investment from Johnson & Johnson Innovation (JJDC), the investment arm of J&J
2023: $30 million strategic investment from Sanofi
2026: MeiraGTx buys back bota-vec gene therapy from J&J, a treatment for X-linked retinitis pigmentosa (XLRP)

Dr. Mark Fisher

Associate Director

Dr Fisher has management responsibility for the BioPharm patent portfolio and strategic business support for the BioPharm team. At the coalface, Mark manages the commercialisation of technology from the Institute of Ophthalmology and Moorfields Eye Hospital UCL Global Business School for Health and the Department of Ageing, Arthritis and Regenerative Medicine.

He holds a first degree in Industrial Biology and a PhD in Biochemistry and Molecular Biology from UCL, in association with one of the first biotechnology companies to be established in the academic sector.

Mark brings more than 30 years of experience in life sciences and healthcare licensing, new company development and securing investment from both the public and private sectors to his team. To date, Mark has been responsible for the establishment of more than 25 new businesses in diagnostics, drug discovery, medical devices and therapeutics.

As a certified lead auditor of ISO 13485, Dr Fisher has additional experience in quality management systems and the translation of technologies from research and design into manufacture at home and abroad.

Mark is a Freeman of the Worshipful Company of Management Consultants and gained the Freedom of the City of London in 2010 for his contribution to the economy through new business development.